Category: 2015

Point Of Care Testing Ltd, (POCT Ltd) is a medical diagnostics distributor of point-of-care instruments and consumables for the medical and research markets in the UK and Ireland. POCT Ltd which also provides services to the National Independent Bowel Cancer Screening Programme, announced today the completion of a share purchase agreement to acquire 100% of the shares of Analox Instruments Ltd, (Analox) a United Kingdom based instrument and reagent manufacturing company. The transaction completed on 6^th February 2015.

Ian Cowie, Managing Director and CEO of Point Of Care Testing Ltd, commented, “Throughout a long and successful period of distributing Point of Care products in the United Kingdom and Ireland, we now take over the additional manufacturing and distribution responsibilities of Analox Instruments by completing this acquisition. The range of products supplied by Analox Instruments is complementary to the POCT product portfolio and it now gives the company access to a global market resulting in a strengthened operational structure. We welcome the highly motivated and experienced Analox employees as new members to the POCT Ltd team. We also believe that in a complex market environment, this acquisition allows us to communicate the superior quality and performance of the POCT Ltd and Analox product ranges to the full benefit of our existing and future customers. Our goal is to build and strengthen our presence in the UK and additional geographic markets and to expand the growth potential of POCT Ltd into the future.” Ian Cowie and POCT was advised by DC Consulting throughout the transaction.

About POCT Ltd and Analox

POCT Ltd, founded in 2002, distributes a range of high quality Point of Care portable blood and urine analysis systems for use in any human patient-care setting in order to provide clinicians with rapid blood constituent measurements, throughout the UK and Ireland. These products include the Abaxis Piccolo xpress™, the Abbott i-STAT®, the Hemoccult® Brand from Beckman Coulter, and a range of ACON Laboratories analysers and rapid tests. POCT Ltd also provides routine laboratory testing for the National Independent Bowel Cancer Screening Programme (NIBCSP).

Analox Instruments, founded in 1973 has over 40 years experience and produces high quality analyser systems for the measurement of a wide variety of analytes including rapid enzymatic analysis for glucose, lactate, cholesterol, urea sucrose, lactose, glycerol, ethanol and methanol with applications in Clinical Research, Biotechnology, Sports Science, Food, Pharmaceuticals, Cosmetics and Beverages. Products are used in over 65 countries world-wide including North America, Japan, Malaysia, Australasia and most European countries. Two thirds of the Company’s output is exported, mostly through distributors.

 

Cellexus Limited, an ambitious Life sciences business has decided to leave its English base and relocate to Scotland.

Cellexus cited Scotland’s reputation as a life sciences hub as well as strong links with academia and the NHS as it moved operations from Cambridgeshire to Dundee. The innovative business received £250,000 of equity match funding from the Scottish Investment Bank, the investment arm of Scottish Enterprise.

Cellexus has a device which produces proteins from bacteria including yeast, e-coli and algae. While the company’s main market is pharmaceuticals and diagnostics the system could also be used in the food and biofuel industries. The company plans to use the funding from the Scottish Investment Bank to enhance its international sales and marketing programme.

Julia Brown, director of life and chemical sciences, Scottish Enterprise, said: “That Cellexus has chosen to move to Dundee from Cambridgeshire is testament to Scotland’s reputation as the location of choice for life sciences companies.  Cellexus is an innovative, forward-thinking company and we look forward to continuing to work with them to help them successfully up-scale and explore new markets, driving forward their ambitious growth plan.”